Opus Genetics, Inc.
IRD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $3 | $3 | $4 | $4 |
| % Growth | 6.8% | -34.1% | 1.6% | – |
| Cost of Goods Sold | $0 | $6 | $0 | $8 |
| Gross Profit | $3 | -$3 | $4 | -$3 |
| % Margin | 99.6% | -109% | 100% | -80.8% |
| R&D Expenses | $6 | $6 | $8 | $7 |
| G&A Expenses | $0 | $6 | $6 | $7 |
| SG&A Expenses | $5 | $6 | $6 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$0 |
| Other Operating Expenses | $0 | -$6 | $0 | $20 |
| Operating Expenses | $11 | $6 | $14 | $35 |
| Operating Income | -$8 | -$9 | -$10 | -$38 |
| % Margin | -269.9% | -309% | -227.2% | -884% |
| Other Income/Exp. Net | -$9 | $1 | $2 | $3 |
| Pre-Tax Income | -$17 | -$7 | -$8 | -$35 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | -$7 | -$8 | -$35 |
| % Margin | -566.9% | -257.5% | -187.5% | -816.7% |
| EPS | -0.25 | -0.12 | -0.24 | -1.11 |
| % Growth | -108.3% | 50% | 78.4% | – |
| EPS Diluted | -0.25 | -0.12 | -0.24 | -1.11 |
| Weighted Avg Shares Out | 71 | 63 | 34 | 32 |
| Weighted Avg Shares Out Dil | 71 | 63 | 34 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$17 | -$9 | -$7 | -$10 |
| % Margin | -564.2% | -308.5% | -155.8% | -233.1% |